LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Strona główna・Stock List・Cogent Biosciences Inc

Cogent Biosciences Inc

Closed

36.27 -1.23

Buy Sell

Overview

Share price change

24h

Current

Min

36.17

Max

37.01

Key metrics
By Trading Economics
Income	-7.4M -81M
EPS	-0.5
Employees	205
EBITDA	-6.8M -79M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+41.61% upside

Dividends
By Dow Jones
Next Earnings	24 lut 2026

Market Stats
By TradingEconomics
Market Cap	3.7B 5.8B
Previous open	37.5
Previous close	36.27

Technical Score

By Trading Central

Confidence

Bearish Evidence

4.88 / 5.87 Support & Resistance

Cogent Biosciences Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 lut 2026, 16:32 UTC

Earnings

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

13 lut 2026, 21:57 UTC

Earnings

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 lut 2026, 21:20 UTC

Earnings

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13 lut 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13 lut 2026, 20:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 lut 2026, 20:45 UTC

Market Talk

Dollar Pares Down Early Losses -- Market Talk

13 lut 2026, 20:39 UTC

Market Talk

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13 lut 2026, 20:28 UTC

Market Talk

Oil Settles Week Lower -- Market Talk

13 lut 2026, 19:51 UTC

Earnings

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 lut 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 lut 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 lut 2026, 19:29 UTC

Earnings

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13 lut 2026, 18:18 UTC

Acquisitions, Mergers, Takeovers

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13 lut 2026, 17:52 UTC

Earnings

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13 lut 2026, 17:16 UTC

Earnings

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 lut 2026, 17:10 UTC

Acquisitions, Mergers, Takeovers

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13 lut 2026, 16:59 UTC

Earnings

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13 lut 2026, 16:39 UTC

Acquisitions, Mergers, Takeovers

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13 lut 2026, 16:11 UTC

Earnings

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13 lut 2026, 16:07 UTC

Market Talk

Hungarian Forint Could Rise Further -- Market Talk

13 lut 2026, 15:54 UTC

Earnings

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13 lut 2026, 15:26 UTC

Market Talk

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13 lut 2026, 15:01 UTC

Earnings

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13 lut 2026, 15:00 UTC

Earnings

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13 lut 2026, 14:50 UTC

Market Talk

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13 lut 2026, 14:44 UTC

Earnings

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13 lut 2026, 14:22 UTC

Market Talk

Earnings

Global Energy Roundup: Market Talk

13 lut 2026, 14:21 UTC

Market Talk

Earnings

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

13 lut 2026, 14:13 UTC

Market Talk

U.S. Natural Gas Futures Move Lower -- Market Talk

Peer Comparison

Price change

Cogent Biosciences Inc Forecast

Price Target

By TipRanks

41.61% upside

12 Months Forecast

Average 52 USD 41.61%

High 67 USD

Low 39 USD

Based on 11 Wall Street analysts offering 12 month price targets forCogent Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Cogent Biosciences Inc - Dist in the past 3 months.

Technical Score

By Trading Central

4.88 / 5.87Support & Resistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.